

Appl. No. : **10/559,647**
Filed : **December 2, 2005**

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

1. (Currently Amended) A Antisense compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a), wherein said compound is at least [[80%]] 90% complementary to nucleotides 12380-13493 as set forth in SEQ ID NO: 4, ~~and wherein said compound inhibits the expression of apolipoprotein(a).~~
2. (Canceled)
3. (Currently Amended) The antisense compound of claim [[2]] 1 comprising an antisense oligonucleotide.
- 4.-5. (Canceled)
6. (Currently Amended) The antisense compound of claim [[4]] 3 comprising a chimeric antisense oligonucleotide.
7. (Canceled)
8. (Currently Amended) The antisense compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
9. (Currently Amended) The antisense compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.
10. (Currently Amended) The antisense compound of claim 1 having at least one phosphorothioate internucleoside linkage.
11. (Currently Amended) The antisense compound of claim 1 having at least one 5-methylcytosine.

Appl. No. : **10/559,647**
Filed : **December 2, 2005**

12.-16. (Canceled)

17. (Original) The antisense compound of claim 1 which is single-stranded.

18.-49. (Canceled)

50. (Currently Amended) The antisense compound of claim 1, wherein the antisense compound comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, and 95.

51. (Canceled)

52. (New) The antisense compound of claim 1, wherein the antisense compound comprises at least 8 contiguous nucleobases of SEQ ID NO: 87 or at least 8 contiguous nucleobases of SEQ ID NO: 88.

53. (New) The antisense compound of claim 1, wherein the antisense compound consists of SEQ ID NO: 87 or SEQ ID NO: 88.

54. (New) The antisense compound of claim 1, wherein the antisense compound is at least 95% complementary to SEQ ID NO: 4.

55. (New) The antisense compound of claim 1, wherein the antisense compound is 100% complementary to SEQ ID NO: 4.

56. (New) The antisense compound of claim 1, wherein the antisense compound is 20 nucleobases in length.

57. (New) A chimeric antisense oligonucleotide 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a), wherein said chimeric antisense oligonucleotide is at least 90% complementary to nucleotides 12380-13493 as set forth in SEQ ID NO: 4.

58. (New) The chimeric antisense oligonucleotide of claim 57, wherein said chimeric antisense oligonucleotide comprises a 2'-deoxynucleotide gap segment positioned between a 5'

Appl. No. : **10/559,647**
Filed : **December 2, 2005**

wing segment and a 3' wing segment.

59. (New) The chimeric antisense oligonucleotide of claim 58, wherein each nucleotide of each wing segment comprises a modified sugar moiety.

60. (New) The chimeric antisense oligonucleotide of claim 59, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

61. (New) The chimeric antisense oligonucleotide of claim 59, wherein the modified sugar moiety is a bicyclic nucleic acid sugar moiety.

62. (New) The chimeric antisense oligonucleotide of claim 57, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

63. (New) The chimeric antisense oligonucleotide of claim 57, wherein each cytosine is a 5-methylcytosine.

64. (New) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is at least 95% complementary to SEQ ID NO: 4.

65. (New) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is 100% complementary to SEQ ID NO: 4.

66. (New) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is 20 nucleobases in length.